JP2019526561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526561A5 JP2019526561A5 JP2019510788A JP2019510788A JP2019526561A5 JP 2019526561 A5 JP2019526561 A5 JP 2019526561A5 JP 2019510788 A JP2019510788 A JP 2019510788A JP 2019510788 A JP2019510788 A JP 2019510788A JP 2019526561 A5 JP2019526561 A5 JP 2019526561A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- alkylene
- composition
- alkyl
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/096472 | 2016-08-24 | ||
| CN2016096472 | 2016-08-24 | ||
| PCT/CN2017/098575 WO2018036498A1 (en) | 2016-08-24 | 2017-08-23 | Entacapone-related compounds to treat macular degeneration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021013670A Division JP7116202B2 (ja) | 2016-08-24 | 2021-01-29 | 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526561A JP2019526561A (ja) | 2019-09-19 |
| JP2019526561A5 true JP2019526561A5 (enExample) | 2020-07-16 |
| JP6898429B2 JP6898429B2 (ja) | 2021-07-07 |
Family
ID=61245496
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510788A Active JP6898429B2 (ja) | 2016-08-24 | 2017-08-23 | 黄斑変性症を治療するためのエンタカポン関連化合物 |
| JP2021013670A Active JP7116202B2 (ja) | 2016-08-24 | 2021-01-29 | 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021013670A Active JP7116202B2 (ja) | 2016-08-24 | 2021-01-29 | 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10980766B2 (enExample) |
| EP (1) | EP3503883B1 (enExample) |
| JP (2) | JP6898429B2 (enExample) |
| CN (1) | CN109689042B (enExample) |
| AU (1) | AU2017317129B2 (enExample) |
| CA (1) | CA3034547C (enExample) |
| WO (1) | WO2018036498A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532976B2 (en) * | 2015-06-23 | 2020-01-14 | National Institute Of Biological Sciences, Beijing | FTO inhibitors |
| CN109689042B (zh) * | 2016-08-24 | 2022-07-12 | 北京生命科学研究所 | 用于治疗黄斑变性的与恩他卡朋相关的化合物 |
| JP7235770B2 (ja) | 2018-05-10 | 2023-03-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤 |
| MA54325A (fr) | 2019-06-05 | 2022-05-11 | Regeneron Pharma | Dispositifs et procédés pour l'administration précise de doses |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| JP2024518143A (ja) * | 2021-04-15 | 2024-04-25 | ブラウン ユニバーシティ | ニトロフェニル－アクリルアミドおよびその使用 |
| US20260035341A1 (en) * | 2022-07-29 | 2026-02-05 | Rpxds Co., Ltd | Fto inhibitors |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2025162373A1 (en) * | 2024-01-30 | 2025-08-07 | National Institute Of Biological Sciences, Beijing | Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway |
| WO2025162358A1 (en) * | 2024-01-30 | 2025-08-07 | Rpxds Co., Ltd | Fto inhibitors of bicyclic structures |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI864875A0 (fi) * | 1986-11-28 | 1986-11-28 | Orion Yhtymae Oy | Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa. |
| US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TW200817315A (en) * | 2006-06-16 | 2008-04-16 | Sanol Arznei Schwarz Gmbh | Entacapone-derivatives |
| EP1946756A1 (en) * | 2007-01-17 | 2008-07-23 | Revotar Biopharmaceuticals AG | Use of entacapone in cosmetic, dermatological and pharmaceutical compositions |
| EP1978014A1 (en) | 2007-04-02 | 2008-10-08 | Esteve Quimica, S.A. | Process for the preparation of entacapone and intermediates thereof |
| DK2173344T3 (en) * | 2007-06-29 | 2016-07-25 | Clarencew Pty Ltd | TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL OR NEURO PSYCHIATRIC DISORDERS USING ocular administration |
| EP2273988B1 (en) * | 2008-04-18 | 2015-09-09 | Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona | L-dopa for treating age-related macular degeneration |
| US20110190356A1 (en) * | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
| AR080888A1 (es) * | 2010-04-12 | 2012-05-16 | R Tech Ueno Ltd | Uso de un derivado de acido graso para producir una composicion oftalmica |
| WO2012142039A1 (en) * | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| EP2908811B1 (en) | 2012-10-17 | 2020-12-09 | Exonate Limited | Compounds useful for treating ocular neovascularisation |
| CN103845317B (zh) | 2012-11-28 | 2018-05-08 | 北京生命科学研究所 | 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用 |
| WO2015095257A2 (en) | 2013-12-18 | 2015-06-25 | Emory University | Managing visual dysfunction or loss of vision for diabetic subjects |
| JP6858712B2 (ja) * | 2015-01-30 | 2021-04-14 | リーバー インスティテュート フォー ブレイン ディベロップメントＬｉｅｂｅｒ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｒａｉｎ Ｄｅｖｅｌｏｐｍｅｎｔ | Ｃｏｍｔ阻害方法及び組成物 |
| CA2975401A1 (en) * | 2015-01-30 | 2016-08-04 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
| CN107922316B (zh) | 2015-06-23 | 2022-04-08 | 北京生命科学研究所 | Fto抑制剂 |
| CN109689042B (zh) * | 2016-08-24 | 2022-07-12 | 北京生命科学研究所 | 用于治疗黄斑变性的与恩他卡朋相关的化合物 |
-
2017
- 2017-08-23 CN CN201780052192.2A patent/CN109689042B/zh active Active
- 2017-08-23 AU AU2017317129A patent/AU2017317129B2/en active Active
- 2017-08-23 WO PCT/CN2017/098575 patent/WO2018036498A1/en not_active Ceased
- 2017-08-23 JP JP2019510788A patent/JP6898429B2/ja active Active
- 2017-08-23 CA CA3034547A patent/CA3034547C/en active Active
- 2017-08-23 EP EP17842920.5A patent/EP3503883B1/en active Active
-
2019
- 2019-02-22 US US16/283,117 patent/US10980766B2/en active Active
-
2021
- 2021-01-29 JP JP2021013670A patent/JP7116202B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Crash-2 Collaborators | The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial | |
| CN114008035A (zh) | 一种shp2磷酸酶变构抑制剂 | |
| Szaliński et al. | Fusarium keratitis—review of current treatment possibilities | |
| JP2018521092A5 (enExample) | ||
| Alkeswani et al. | Treatment of tinea capitis | |
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| Roy et al. | The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials | |
| JP2018523689A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2011528713A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| JP2007520452A5 (enExample) | ||
| JP2020523356A5 (enExample) | ||
| ES2405323T3 (es) | Tratamiento de melanoma | |
| Borgia et al. | Prophylaxis of ocular infection in the setting of intraocular surgery: implications for clinical practice and risk management | |
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| JP2018138596A5 (enExample) | ||
| Maccari et al. | Can allostery be a key strategy for targeting PTP1B in drug discovery? A lesson from trodusquemine | |
| ES2924728T3 (es) | Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas | |
| JP2020510045A5 (enExample) | ||
| Zhang et al. | Noncovalent bile acid oligomers as facial amphiphilic antimicrobials | |
| JP2008540528A5 (enExample) | ||
| CA2608163A1 (en) | Hydralazine compositions and methods | |
| CN110461329A (zh) | 治疗血癌的PPARγ激动剂 | |
| JP2021502379A5 (enExample) |